• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过时间推移解读肝细胞癌的流行病学:一项对跨越3个十年的1401例患者的研究。

Deciphering the epidemiology of hepatocellular carcinoma through the passage of time: A study of 1,401 patients across 3 decades.

作者信息

Goh George Boon-Bee, Li James Weiquan, Chang Pik-Eu, Chow Khuan-Yew, Tan Chee-Kiat

机构信息

Department of Gastroenterology and Hepatology Singapore General Hospital Singapore.

Duke-NUS Medical School Singapore.

出版信息

Hepatol Commun. 2017 Jun 14;1(6):564-571. doi: 10.1002/hep4.1059. eCollection 2017 Aug.

DOI:10.1002/hep4.1059
PMID:29404479
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5678902/
Abstract

Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers globally. With advances in therapy for chronic viral hepatitis, changing social circumstances, and increasing practice of HCC surveillance, the epidemiology of HCC is expected to change over time. We explored the temporal trends in HCC in Singapore, a multiethnic Asian country, over the last 3 decades. Patients with HCC were prospectively enrolled and stratified into two cohorts (C1, 1988-2002; C2, 2003-2016). Patient and tumor characteristics, management, and survival were compared between the two cohorts, and a survival census was performed on October 31, 2015. There were 1,401 patients, and the mean age at diagnosis of HCC for C1 and C2 was 60.1 and 63.5 years, respectively. Male patient preponderance decreased significantly, with the male to female ratio falling from 5.2:1 to 3.9:1 between C1 and C2. Hepatitis B, although still the predominant risk factor for HCC, showed a significant decline from C1 to C2 (76.5% to 68.2%), while the nonviral etiology increased significantly over the same period (14.4% versus 25.0%, respectively). Significantly more patients in C2 than C1 were diagnosed through surveillance (39.2% versus 11.3%, respectively) and had better physical performance (Eastern Cooperative Oncology Group 0, 62.1% versus 20.4%, respectively). While Child-Pugh status was comparable, significantly more patients in C2 than C1 had early stage disease (Barcelona Clinic Liver Cancer 0-A, 39.5% versus 7.4%, respectively), which translated into significantly higher median survival (18.6 months versus 3.8 months, respectively). : Over the past 3 decades, hepatitis B-related HCC has been decreasing while HCC due to nonviral etiology has been increasing significantly. Surveillance to diagnose early stage HCC is important in improving the outcome of HCC. ( 2017;1:564-571).

摘要

肝细胞癌(HCC)是全球最常见且致命的癌症之一。随着慢性病毒性肝炎治疗方法的进步、社会环境的变化以及HCC监测工作的日益普及,预计HCC的流行病学情况会随时间发生改变。我们探究了过去30年里新加坡这个多民族亚洲国家HCC的时间趋势。对HCC患者进行前瞻性登记,并分为两个队列(C1,1988 - 2002年;C2,2003 - 2016年)。比较了两个队列之间的患者和肿瘤特征、治疗情况及生存率,并于2015年10月31日进行了生存普查。共有1401例患者,C1和C2队列中HCC诊断时的平均年龄分别为60.1岁和63.5岁。男性患者占优势的情况显著下降,C1和C2队列之间的男女比例从5.2∶1降至3.9∶1。乙型肝炎虽然仍是HCC的主要危险因素,但从C1到C2显著下降(从76.5%降至68.2%),而同期非病毒病因显著增加(分别为14.4%和25.0%)。C2队列中通过监测诊断出的患者显著多于C1队列(分别为39.2%和11.3%),且身体状况更好(东部肿瘤协作组0级,分别为62.1%和20.4%)。虽然Child-Pugh分级情况相当,但C2队列中处于疾病早期(巴塞罗那临床肝癌0 - A期)的患者显著多于C1队列(分别为39.5%和7.4%),这使得C2队列的中位生存期显著更长(分别为18.6个月和3.8个月)。在过去30年里,乙型肝炎相关的HCC一直在减少,而非病毒病因导致的HCC则显著增加。监测以诊断早期HCC对改善HCC的预后很重要。(2017;1:564 - 571)

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e19d/5678902/546f565bc7fb/HEP4-1-564-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e19d/5678902/546f565bc7fb/HEP4-1-564-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e19d/5678902/546f565bc7fb/HEP4-1-564-g001.jpg

相似文献

1
Deciphering the epidemiology of hepatocellular carcinoma through the passage of time: A study of 1,401 patients across 3 decades.通过时间推移解读肝细胞癌的流行病学:一项对跨越3个十年的1401例患者的研究。
Hepatol Commun. 2017 Jun 14;1(6):564-571. doi: 10.1002/hep4.1059. eCollection 2017 Aug.
2
Comparison of Hepatocellular Carcinoma in Patients with Cryptogenic Versus Hepatitis B Etiology: A Study of 1079 Cases Over 3 Decades.对比隐匿性病因与乙型肝炎病因的肝细胞癌患者:30 年来 1079 例病例研究。
Dig Dis Sci. 2019 Feb;64(2):585-590. doi: 10.1007/s10620-018-5331-x. Epub 2018 Oct 16.
3
Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population.乙型肝炎病毒流行地区肝细胞癌患者的生存时间得到改善。
J Gastroenterol Hepatol. 2018 Feb;33(2):475-483. doi: 10.1111/jgh.13848.
4
Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience.临床实践中肝细胞癌预后改善趋势:一项意大利实地经验
Dig Dis Sci. 2015 May;60(5):1465-73. doi: 10.1007/s10620-014-3427-5. Epub 2014 Nov 16.
5
Lack of association of cytochrome P450 2E1 genetic polymorphisms with the risk of human hepatocellular carcinoma.细胞色素P450 2E1基因多态性与人类肝细胞癌风险之间缺乏关联。
Int J Cancer. 1997 May 29;71(5):737-40. doi: 10.1002/(sici)1097-0215(19970529)71:5<737::aid-ijc8>3.0.co;2-s.
6
Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.某流行地区2293例慢性乙型肝炎患者的肝细胞癌筛查与监测
World J Gastroenterol. 2016 Sep 14;22(34):7806-12. doi: 10.3748/wjg.v22.i34.7806.
7
Clinicopathologic characteristics andoutcomes of hepatocellular carcinoma associated with chronic hepatitis B versus hepatitis C infection.慢性乙型肝炎与丙型肝炎感染相关肝细胞癌的临床病理特征及预后
Ann Saudi Med. 2018 Sep-Oct;38(5):358-365. doi: 10.5144/0256-4947.2018.358.
8
Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database.巴塞罗那临床肝癌B期和C期肝细胞癌的亚分类:一项多中心注册数据库队列研究
J Gastroenterol Hepatol. 2016 Apr;31(4):842-7. doi: 10.1111/jgh.13218.
9
Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation.经射频消融治疗后肝细胞癌患者的病毒病因预后比较。
Ann Hepatol. 2013 Mar-Apr;12(2):263-73.
10
Gender survival differences in hepatocellular carcinoma: Is it all due to adherence to surveillance? A study of 1716 patients over three decades.肝细胞癌的性别生存差异:这一切都归因于对监测的依从性吗?一项对1716例患者长达三十年的研究。
JGH Open. 2023 Apr 24;7(5):377-386. doi: 10.1002/jgh3.12910. eCollection 2023 May.

引用本文的文献

1
Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria.程序性死亡蛋白1(PD-1)抑制剂(信迪利单抗)联合经动脉化疗栓塞术作为超出米兰标准的中期肝细胞癌患者初始治疗的安全性和有效性
J Immunother Cancer. 2025 Jan 16;13(1):e010035. doi: 10.1136/jitc-2024-010035.
2
Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study.亚太地区肝细胞癌诊断、治疗与管理的真实世界数据:洞察研究
Liver Cancer. 2023 Oct 9;13(3):298-313. doi: 10.1159/000534513. eCollection 2024 Jun.
3

本文引用的文献

1
Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities.根据基础疾病和治疗方式对肝细胞癌患者进行死亡率评估。
Medicine (Baltimore). 2017 Mar;96(9):e5904. doi: 10.1097/MD.0000000000005904.
2
Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study.核苷类似物治疗乙型肝炎对香港肝癌发病率的影响:一项全港范围的生态学研究。
Aliment Pharmacol Ther. 2017 Feb;45(4):501-509. doi: 10.1111/apt.13895. Epub 2016 Dec 15.
3
The evolutionary scenario of hepatocellular carcinoma in Italy: an update.
Gender survival differences in hepatocellular carcinoma: Is it all due to adherence to surveillance? A study of 1716 patients over three decades.
肝细胞癌的性别生存差异:这一切都归因于对监测的依从性吗?一项对1716例患者长达三十年的研究。
JGH Open. 2023 Apr 24;7(5):377-386. doi: 10.1002/jgh3.12910. eCollection 2023 May.
4
Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study.TACE联合阿替利珠单抗加贝伐单抗治疗超过七项标准的中期肝细胞癌患者的早期经验:一项多中心单臂研究
J Oncol. 2023 Apr 15;2023:6353047. doi: 10.1155/2023/6353047. eCollection 2023.
5
An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma.肝细胞癌和胆管癌新型免疫疗法及靶向治疗策略洞察
Life (Basel). 2022 Apr 30;12(5):665. doi: 10.3390/life12050665.
6
Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection.台湾一个非慢性乙肝/丙肝感染的社区人群中肝细胞癌的发病率。
JHEP Rep. 2021 Nov 24;4(2):100410. doi: 10.1016/j.jhepr.2021.100410. eCollection 2022 Feb.
7
A study of 3013 cases of hepatocellular carcinoma: Etiology and therapy before and during the current decade.一项对3013例肝细胞癌病例的研究:当前十年前后的病因及治疗情况。
JGH Open. 2021 Jul 27;5(9):1015-1018. doi: 10.1002/jgh3.12624. eCollection 2021 Sep.
8
Clinical Features and Overall Survival of Females with Hepatocellular Carcinoma: A Retrospective Study and Review of the Literature in the Association of Southeast Asian Nations.东南亚国家联盟女性肝细胞癌的临床特征与总生存期:一项回顾性研究及文献综述
Int J Womens Health. 2021 Jul 22;13:717-725. doi: 10.2147/IJWH.S311419. eCollection 2021.
9
Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion.亚太地区晚期肝细胞癌的治疗进展:综述与多学科专家意见
Cancers (Basel). 2021 May 27;13(11):2626. doi: 10.3390/cancers13112626.
10
"Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma.“赞美补体”:肝细胞癌治疗的机制见解与机遇
Front Oncol. 2021 Feb 24;10:627701. doi: 10.3389/fonc.2020.627701. eCollection 2020.
意大利肝细胞癌的进化情况:更新。
Liver Int. 2017 Feb;37(2):259-270. doi: 10.1111/liv.13204. Epub 2016 Aug 17.
4
International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007.1978 - 2007年肝癌发病率的国际趋势,总体及按组织学亚型划分的趋势
Int J Cancer. 2016 Oct 1;139(7):1534-45. doi: 10.1002/ijc.30211. Epub 2016 Jun 28.
5
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030.美国肝细胞癌发病率至2030年的预测前景
J Clin Oncol. 2016 May 20;34(15):1787-94. doi: 10.1200/JCO.2015.64.7412. Epub 2016 Apr 4.
6
Changing epidemiology of hepatocellular carcinoma in Asia.亚洲肝细胞癌流行病学的变化
Best Pract Res Clin Gastroenterol. 2015 Dec;29(6):919-28. doi: 10.1016/j.bpg.2015.09.007. Epub 2015 Sep 10.
7
Perceptions of non-alcoholic fatty liver disease - an Asian community-based study.非酒精性脂肪性肝病的认知 - 一项亚洲社区为基础的研究。
Gastroenterol Rep (Oxf). 2016 May;4(2):131-5. doi: 10.1093/gastro/gov047. Epub 2015 Oct 12.
8
The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years?肝细胞癌患者的管理与预后:20年来有哪些变化?
Liver Int. 2016 Mar;36(3):445-53. doi: 10.1111/liv.12960. Epub 2015 Oct 12.
9
Changing incidence patterns of hepatocellular carcinoma among age groups in Taiwan.台湾地区各年龄段人群肝细胞癌发病率变化模式。
J Hepatol. 2015 Dec;63(6):1390-6. doi: 10.1016/j.jhep.2015.07.032. Epub 2015 Aug 6.
10
Androgen receptor in hepatocarcinogenesis: Recent developments and perspectives.雄激素受体在肝癌发生中的作用:最新进展与展望
Oncol Lett. 2015 May;9(5):1983-1988. doi: 10.3892/ol.2015.3025. Epub 2015 Mar 10.